A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency

Molecular Genetics and Metabolism

Volumn 96, Issue 3, 2009, Pages 85-90

  Arnold, Georgianne L ^a   Van Hove, Johan ^b   Freedenberg, Debra ^c   Strauss, Arnold ^d   Longo, Nicola ^e   Burton, Barbara ^f   Garganta, Cheryl ^g   Ficicioglu, Can ^h   Cederbaum, Stephen ⁱ   Harding, Cary ^j   Boles, Richard G ^k   Matern, Dietrich ^l   Chakraborty, Pranesh ^m   Feigenbaum, Annette ⁿ  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g TUFTS MEDICAL CENTER   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^k UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^l Laboratory Medicine and Pathology   (United States)

^m UNIVERSITY OF OTTAWA   (Canada)

ⁿ HOSPITAL FOR SICK CHILDREN   (Canada)

more..

Author keywords

Clinical practice protocol; Delphi; Fatty acid oxidation; Newborn screening; Very long chain acyl CoA dehydrogenase deficiency (VLCAD)

Indexed keywords

ACYLCARNITINE; BEZAFIBRATE; CARNITINE; LONG CHAIN ACYL COENZYME A DEHYDROGENASE;

ARTICLE; BREAST FEEDING; CARDIOMYOPATHY; CLINICAL PRACTICE; CONTROLLED STUDY; DIET RESTRICTION; DIET SUPPLEMENTATION; DNA DETERMINATION; ENZYME ASSAY; ENZYME DEFICIENCY; FATTY ACID OXIDATION; HUMAN; INFANT; MEDICAL ASSESSMENT; MEDICAL EXPERT; MOUSE; MYOPATHY; NEWBORN SCREENING; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME; VERY LONG CHAIN ACYL COA DEHYDROGENASE DEFICIENCY;

ACYL-COA DEHYDROGENASE, LONG-CHAIN; CLINICAL PROTOCOLS; DELPHI TECHNIQUE; DISEASE MANAGEMENT; FEMALE; HUMANS; INFANT; LIPID METABOLISM, INBORN ERRORS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 60649111860     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2008.09.008     Document Type: Article

References (30)

1. Gregerson N., Andresen B.S., Corydon M.J., Corydon T.J., Olsen R., Bolund L., and Bross P. Mutation anaysis in mitochondrial fatty acid oxidation defects, exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship. Hum. Mutat. 18 (2001) 169-189
2. Millington D.S., Kodo N., Norwood D.L., and Roe C.R. Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors if metabolism. J. Inherit. Metab. Dis. 13 (1990) 321-324
3. Boneh A., Andresen B.S., Gregersen N., Ibrahim M., Tzanakos N., Peters H., Yaplito-Lee Y., and Pitt J.J. VLCAD deficiency: Pitfalls in newborn screening and confirmation of diagnosis by mutation analysis. Mol. Genet. Metab. 88 (2006) 166-170
4. Centre for Evidence-Based Medicine, Available from: (accessed May 2, 2008).
5. H.A. Linstone, M. Turof, The Delphi method: techniques and applications, Addison-Wesley Pub. Co., Reading, Mass, 1975, Available from: (accessed online May 1, 2008).
6. Powell C. The Delphi technique: myths and realities. J. Adv. Nurs. 41 (2003) 376-382
7. Arnold G.L., Koeberl D.D., Matern D., Barshop B., Braverman N., Burton B., Cederbaum S., Feigenbaum A., Garganta C., Gibson J., Goodman S.I., Harding C., Kahler S., Kronn D., and Longo N. A Delphi-based consensus clinical practice protocol for the diagnosis and management of 3-methylcrotonyl CoA carboxylase deficiency. Mol. Genet. Metab. 93 4 (2008) 363-370
8. Murphy M.K., Black N.A., Lamping D.L., McKee C.M., Sanderson C.F., Askham J., and Marteau T. Consensus development methods, and their use in clinical guideline development. Health Technol. Assess 2 (1998) 1-88
9. G. Berry, S.I. Goodman, D. Marsden, D. Matern, W. Nyhan. Newborn screening ACT sheet [very long chain acyl-CoA dehydrogenase deficiency], American College of Medical Genetics ACT sheet, Available from: (accessed on May 1, 2008).
10. Liebig M., Schymik I., Mueller M., Wendel U., Mayatepek E., Ruiter J., Strauss A.W., Wanders R.J.A., and Spiekerkoetter U. Neonatal screening for very long-chain acyl-CoA dehydrogenase deficiency; enzymatic and molecular evaluation of neonates with elevated C14:1-carnitine levels. Pediatrics 118 (2006) 1065-1069
11. G. Berry, S.I. Goodman, D. Marsden, D. Matern, W. Nyhan. Newborn Screening ACT Sheet [Very Long Chain Acyl-CoA Dehydrogenase Deficiency], American College of Medical Genetics ACT sheet, Available from: (accessed on May 1, 2008).
12. Schymik I., Liebig M., Mueller M., Wemdel U., Mayatepek E., Strauss A.W., Wanders R.J.A., and Spiekerkoetter U. Pitfalls of neonatal screening for very-long-chain acyl CoA dehydrogenase deficiency using tandem mass spectrometry. J. Pediatr. 149 (2006) 128-130
13. Browning M.F., Larson C., Strauss A., and Marsden D.L. Normal acylcarnitine levels during confirmation of abnormal newborn screening in long-chain fatty acid oxidation defects. J. Inherit. Metab. Dis. 28 (2005) 545-550
14. Andresen B.S., Olpin S., Poorthius J.H.M., Scholte H.R., Vianey-Saban C., Wanders R., Ijlsst L., Morris A., Pourfarzam M., Bartlett K., Baumgartner E.R., deKlerk B.C., Schroeder L.D., Corydon T.J., Lund H., Winter V., Bross P., Bolund L., and Gregerson N. Clear Correlation of genotype with disease phenotype in very-long-chain-acyl-CoA dehydrogenase deficiency. Am. J. Hum. Genet. 64 (1999) 479-494
15. Spiekerkoeter U., Sun B., Zytkovic T., Wanders R., Strauss A.W., and Wendel U. MS/MS-based newborn and family screening detects asymptomatic patients with very-long-chain acyl-CoA dehydrogenase deficiency. J. Pediatr. 143 (2003) 335-342
16. Mathur A., Sims H.F., Gopalakrishnan D., Gibson B., Rinaldo P., Vockley J., Hug G., and Strauss A.W. Molecular heterogeneity in very long chain acyl CoA dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death. Circulation 99 (1999) 1337-1343
17. E.G. Neilan, unpublished data, communicated May 6, 2008.
18. Roe D.S., Vianey-Saban C., Sharma S., Zabot M.-T., and Roe C.R. Oxidation of unsaturated fatty acids by human fibroblasts with very-long-chain acyl-CoA dehydrogenase deficiency: aspects of substrate specificity and correlation with clinical phenotype. Clin. Chim. Acta 312 (2001) 55-67
19. Zytkovicz T.H., Fitzgerald E.F., Marsden D., Larson C.A., Shih V.E., Johnson D.M., Strauss A.W., Comeau A.M., Eaton R.B., and Grady G.F. Tandem mass spectrometric analysis for amino, organic and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin. Chem. 47 (2001) 1945-1955
20. Wood J.C., Magera M.J., Rinaldo P., Seashore M.R., Strauss A.W., and Friedman A. Diagnosis of very long chain acyl-dehydrogenase deficiency from an infant's newborn screening card. Pediatrics 108 (2001) e19
21. Cox G.F., Souri M., Aoyama T., Rochenmacher S., Varvogli L., Rohr F., Hashimoto T., and Korson M.S. Refersal of severe hypertrophic cardiomyopathy and excellent neuropsychologic outcome in very-long-chain acyl-coenzyme A dehydrogenase deficiency. J. Pediatr. 133 (1998) 247-253
22. Brown-Harrison M.C., Nada M.A., Sprecher H., Vianey-Saban C., Farquhar J., Gilladoga A.C., and Roe C.R. Very long chain acyl-CoA dehydrogenase deficiency: successful treatment of acute cardiomyopathy. Biochem. Mol. Med. 58 (1996) 59-65
23. New England Consortium of Metabolic Programs, Available from: (accessed May 1, 2008).
24. Spiekerkoetter U., Tokunaga C., Wendel U., Mayatepek E., Exil V., Duran M., Wijburg F.A., Wanders F.J.A., and Strauss A.W. Changes in blood carnitine and acylcarnitine profiles of very long-chain acyl-CoA dehydrogenase-deficient mice subjected to stress. Eur. J. Clin. Invest. 34 (2004) 191-196
25. Bonnet D., Martin D., de Lonlay P., Villian E., Jouvet P., Rabier D., Brivet M., and Saudubray J.-M. Arrhythmias and conduction defects as p resenting symptoms of fatty acid oxidation disorders in children. Circulation 100 (1999) 2248-2253
26. Madden M.C., Wolkowitcz P.E., Pohost G.M., McMillan J.B., and Pike M.M. Acylcarnitine accumulation does not correlate with reperfusion recovery in palmitate-perfused rat hearts. Am. J. Physiol. 268 (1995) H2505-H2512
27. Liebig M., Gyenes M., Brauers G., Ruiter J.P.N., Wendel U., Mayatepek E., Strauss A.W., Wanders R.J.A., and Spiekerkoetter U. Carnitine supplementation induces long-chain acylcarnitine production-studies in the VLCAD-deficient mouse. J. Inherit. Metab. Dis. 29 (2006) 343-344
28. Spiekerdoetter U., Tokunaga C., Wendel U., Mayatepek E., Ijlst L., Vaz F.M., Van Vlies N., Overmars H., Duran M., Wijburg F.A., Wanders R.J., and Strauss A.W. Tissue carnitine homeostasis in very-long-chain acyl-CoA dehydrogenase-deficient mice. Pediatr. Res. 57 (2005) 760-764
29. Djouadi F., Aubey F., Schlemmer D., Ruiter J.P., Wanders R.J., Strauss A.W., and Bastin J. Benzafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. Hum. Mol. Genet. 14 (2005) 2695-2703
30. Gobin-Limballe S., Djouadi F., Aubrey F., Olpin S., Andresen B.S., Yamaguchi S., Mandel H., Fukao T., Ruiter J.P.N., Wanders R.J.A., McAndrew R., Kim J.J., and Bastin J. Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by benzafibrate in patient fibroblasts: toward a genotype-based therapy. Am. J. Hum. Genet. 81 (2007) 1133-1143